In This Article:
H.C. Wainwright initiated coverage of Zenas BioPharma (ZBIO) with a Buy rating and $30 price target The company’s lead autoimmune therapy, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and Fc gamma receptor IIb, FcgammaRIIb, broadly present on B cell lineage, the analyst tells investors in a research note. The firm believes obexelimab represents an autoimmune franchise molecule with the potential for B cell therapeutic differentiation.
Pick the best stocks and maximize your portfolio:
-
Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
-
Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ZBIO: